| Drug name | Tramenitib |
| Phase | III |
| Indication | BRAFV600 mutant metastatic melanoma |
| Pharmacology | Inhibitor of MEK 1 and 2, resulting in growth factor-mediated inhibition of cell signalling and proliferation |
| Route of administration | Oral |
| Chemical structure | N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl) acetamide |
| Pivotal trial(s) | Phase I [15, 26, 32], Phase II [15, 47], Phase III [14, 18, 19] |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.